Avalon is a clinical-stage, vertically integrated, leading “CellTech” bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well related diagnostics and therapeutics.
The Company also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth and development, as well as competitiveness in healthcare and CellTech industry markets.
Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, the Company is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and other related vaccine and therapeutics.
Their core focus at the moment is their 3rd Generation CAR-T therapy that can potentially be useful in the treatment of cancer and other life-threatening diseases along with their FLASH-CAR technology and stem cell derived Exosome technology called ACTEX. ACTEX can be used to treat a wide variety of conditions, from neurodegenerative disorders to immune health, orthopedic applications, wound management and even weight management.
Avalon GloboCare successfully filed for a $50Mn shelf offering (S3) in January of 2019, and was also staked a $20Mn credit facility from Chairman Daniel Lu.
That same Daniel Lu also happens to be chairman of the Lu DaoPei hospital group, China’s largest hematology and CAR-T treatment center.
Those types of connections are key to Avalon GloboCare’s vertical integration:
Upstream: Innovation, R&D, IPs
- QTY-code engineered novel targets; AVA-Trap ™
- Next-Gen multi-target, RNA-based Flash-CAR ™
- Angiogenic Exosomes; ACTEX ™
Midstream: Process development, Bio-production, QC/QA
- UPMC: Accredited cGMP/cGTP/FACT/aaBB/CLIA/CAP Facility
Downstream: Clinical Programs
- Medical Team: Lu Daopei Hospital network and over 100 affiliated hospitals, the world’s single largest BMT and CAR-T treatment center;
- Commercialization: B-to-B model for product development and global marketing (ACTEX ™ecosystem)
This kind of integration is a tremendous advantage for companies working in the clinical stage of the process, because it gives Avalon GloboCare a real-world path to market (and to potential revenues) without the imminent need to involve third parties or secure new funding.
That means the company has a direct pipeline that can take compelling research and new ideas, rapidly transform them into a marketable product, and then potentially fast-track the testing process.
Their lead CAR-T candidate, AVA-001, has already completed a pilot first-in-human trial in patients with B-cell acute lymphoblastic leukemia with a stated remission rate far higher than the industry standard.
Avalon is currently expanding patient recruitment and indication.
Read more key details at the company website and check out their presentation here.
-----
And right now, 5 potential catalysts could fuel a vertical chart move in the near term for AVCO. They are:
No. 1 AVCO Potential Catalyst - A Game-Changing New Study Featuring AI Enhanced Protein Design "QTY Code" Tech
Avalon GloboCare Announces New Study Featuring AI-Enhanced Protein Design Technology Targeting Glucose Transporter Against Cancer
FREEHOLD, N.J., June 30, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, today announced a new study applying artificial intelligence (AI) enhanced protein design “QTY Code” technology. The method is expected to accelerate development of therapeutic monoclonal antibodies to treat cancer.
...
“This new publication with our collaborator, Professor Zhang from MIT, using the QTY code has demonstrated a novel method for quickly predicting the structures of water-soluble versions of glucose transporter proteins, which are proteins important in cancer,” said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon. “This is an important discovery as these proteins are difficult to study and so far, poorly understood. These transport proteins, especially those that regulate glucose, play a vital role in the growth of cancer. We believe our method will accelerate our understanding of these proteins and the development of antibodies against them to treat cancer.”
...
Read the full article here.
-----
No. 2 AVCO Potential Catalyst - Count Them: 16 New Patent Applications Filed
Avalon GloboCare Expands IP Portfolio; Files 16 New Patent Applications
Co-inventors are leading international universities and cellular therapy developers
Patent applications cover three types of cellular therapies and related technologies
Read the full article here.
-----
No. 3 AVCO Potential Catalyst - Low Float Profile Provides Possibility For Daily Volatility
At 31.39Mn shares, the Yahoo Finance website is reporting AVCO to have relatively small float.
In recent days, we've noticed a few, big, intraday green spikes on AVCO's chart.
Could volatility from so few shares available be leading to this?
-----
No. 4 AVCO Potential Catalyst - Company Signs MOU With "Prestigious" Hematology Institute (Could Expand AVCO's Pipeline Immensely)
Avalon GloboCare Signs MOU...
From the article:
“It is an honor to form this strategic collaboration with the researchers and clinicians at the prestigious Lu Daopei Hematology Institute to advance the clinical development of potentially breakthrough cellular immunotherapies along with companion diagnostics,” said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare.
Read the full article here.
-----
AVCO Recap: 5 Potential Catalysts Could Fuel A Vertical Move For This Nasdaq Profile
No. 1 - A Game-Changing New Study Featuring AI Enhanced Protein Design "QTY Code" Tech
No. 2 - Count Them: 16 New Patent Applications Filed
No. 3 - Low Float Profile Provides Possibility For Daily Volatility
No. 4 - Company Signs MOU With "Prestigious" Hematology Institute (Could Expand AVCO's Pipeline Immensely)
-----
Coverage is officially initiated on AVCO. When time permits, do this:
